Careers
Contact Us
Navigate Adaptimmune Limited
Home
Our Company
Overview
Board of Directors
Management & Founders
Partners
Scientific Advisory Board
Pipeline
Overview
ADP-A2M10 (MAGE-A10)
ADP-A2M4 (MAGE-A4)
ADP-A2AFP (AFP)
Technology
Overview
The Immune System
Our Engineered T-Cell Therapies
Our Technology Platform
Manufacturing
Intellectual Property
Publications
Patients & Families
Overview
Our Clinical Trials
Taking Part in our Clinical Trials
Clinical Trial FAQ
Cancer Information
Cancer Immunotherapy Month
News & Events
News
Scientific Conferences
Investor Conferences
Investors
Focusing on the needs of our patients
Learn More
Enhancing the Affinity of T-cell to Fight Cancer
Learn More
Investigating SPEAR T-Cell Therapy in 10 Solid Tumors
Learn More
Working with Leading Experts to Transform T-cell Therapy for Cancer Patients
Learn More
Latest News •
View all
January 7, 2019
Dose Escalation in Liver Cancer Study with ADP-A2AFP (AFP) SPEAR T-cells and Moving to Expansion Phase in ADP-A2M10 (MAGE-A10) Lung Cancer Study after Favorable Safety Reviews
December 12, 2018
Adaptimmune Announces that Gwen Binder will leave in January 2019
November 6, 2018
Adaptimmune Reports Third Quarter 2018 Financial Results and Business Update
Adaptimmune on Linkedin
Adaptimmune on Twitter
Tweets by Adaptimmune
The Immune System
Clinical Trials
Our Pipeline
Manufacturing
Partnerships
